Duke University Researchers have developed a breakthrough nasal test designed to detect Alzheimer’s disease before memory loss appears.
A Duke Health study, published in Nature Communications on Wednesday, March 18, reveals a simple nasal swab test can identify Alzheimer’s before symptoms appear. The test detects early biological signals and biomarkers of the disease. Researchers report that this experimental diagnostic tool may help identify the disease in its preclinical stage, prior to cognitive decline.
The National Institute of Health (NIH) funded study was led by Duke surgeon-scientist Dr. Bradley J. Goldstein, who sees this device as a potential medical breakthrough.
“If we can diagnose people early enough, we might be able to start therapies that prevent them from ever developing clinical Alzheimer’s,” said Dr. Goldstein in a statement.
The Duke Health researchers theorized that analyzing nasal neural tissue could serve as a “window” into the brain, bypassing the need for invasive brain biopsies. This breakthrough provides a non-invasive framework to study early disease mechanisms directly within accessible human tissue.
Researchers used single-cell RNA sequencing to analyze samples from 22 subjects. The test achieved 81% accuracy in detecting the disease.
The nasal swab test is part of a growing theory in neurology that the nose is an early warning system for Alzheimer’s. The researchers noted that loss of smell is strongly associated with the development of Alzheimer’s. Yet, the biological reason for the link has remained unexplained.
How Does The Experimental Device Work?
According to the study, the test takes only a few minutes. It starts with a clinician applying numbing spray to the patient. The clinician then uses a small brush to swab the olfactory region, located in the roof of the nasal cavity. An endoscope guides the olfactory brush. Doctors collect samples of the nerve and immune cell from the olfactory region.
Following sample collection, researchers use single-cell RNA sequencing to analyze gene activity by tracking mRNA signals in each individual cell. By comparing the genetic activity of healthy individuals to those with Alzheimer’s, they can identify specific “cellular signatures” of the disease. From this data, they use a gene-based score to determine the biological state of the brain.
By identifying Alzheimer’s markers before memory loss, doctors offer a potential way to study the disease’s progression in real time.
The History Of Alzheimer’s Disease Detection
Up until the early 2000s, autopsies were the only way to definitively confirm the physical hallmark of the disease. Due to this limitation, much of the historical understanding was based on analysis of end-stage tissue after severe, irreversible neuron damage had already occurred.
Researchers then identified more definitive ways to detect Alzheimer’s in living bodies. Studies report PET scans have a 90-95% accuracy. However, the scans are expensive and inaccessible to some due to the use of specialized equipment and practice. Similarly, spinal taps have high accuracy rate, but are categorized as expensive and invasive.
NIH funding is prioritizing innovative approaches in early disease detection at preclinical stage. While the Duke Nasal Swab test is the newest experimental innovation, it is not the first.
The Food and Drug Administration cleared the first Alzheimer’s diagnostic blood tests — Lumipulse and Elecsys pTau181 — for clinical use in 2025. Per the FDA, clinicians should only use these tests to confirm a diagnosis in patients already showing signs of cognitive decline because they only detect Alzheimer’s after significant disease progression. Biomarkers must first reach measurable levels in the blood for the tests to work efficiently.
When Will This Alzheimer’s Test Be Available For Practices?
The nasal swab test is currently experimental and not yet available for clinician or patient use. The March 2026 study served as a “proof of concept,” involving only 22 test subjects.
To achieve FDA clearance, future studies will require much larger sample populations to establish the statistically significant confidence intervals necessary for diagnostic approval.
The Duke Health team plans to expand the research in collaboration with the Duke & UNC Alzheimer’s Disease Research Center. Duke University has also filed a U.S. patent for the specific single-cell RNA sequencing approach and “nose tissue score” as they continue to develop the test.
Currently approved diagnostic tests include blood tests, spinal taps, and brain scans, such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Positron Emission Tomography (PET).
Clinicians typically use diagnostic tests in combination with a patient’s medical history, physical exams, and cognitive assessments to diagnose the disease.
